Bevacizumab: současné postavení v léčbě solidních nádorů
| Title in English | Bevacizumab: current status of malignant tumors treatment |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | angiogenesis; bevacizumab; VEGF; solid tumors |
| Description | Angiogenesis is a key process in growth and metastatic spread of malignant tumors. Enthusiastic research over past years has produced several therapeutic agents targeting angiogenesis, available in clinical practice. The most advanced in the treatment of solid tumors at present time is bevacizumab, a humanized monoclonal anti-VEGF antibody. It has become a part of standard treatment of metastatic colorectal cancer and is settling in the treatment of breast, kidney and lung cancers. To determine the role of bevacizumab in the treatment of other solid malignancies, there are many clinical trials ongoing. The toxicity profile has been well described and is quite favorable. The article brings a basic overview of the clinical use of bevacizumab based on clinical studies. |